Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering.
Lee D, Dunn ZS, Guo W, Rosenthal CJ, Penn NE, Yu Y, Zhou K, Li Z, Ma F, Li M, Song TC, Cen X, Li YR, Zhou JJ, Pellegrini M, Wang P, Yang L.
Lee D, et al. Among authors: penn ne.
Nat Commun. 2023 Nov 8;14(1):6942. doi: 10.1038/s41467-023-42619-2.
Nat Commun. 2023.
PMID: 37938576
Free PMC article.